| Ident. | Authors (with country if any) | Title |
|---|
| 000054 (2015) |
Paolo Solla [Italie] ; Alfonso Fasano [Canada] ; Antonino Cannas [Italie] ; Francesco Marrosu [Italie] | Suicide and dopamine agonist withdrawal syndrome in Parkinson's disease. |
| 000223 (2015) |
Isabelle Beaulieu-Boire [Canada] ; Alfonso Fasano [Canada] | Graft-induced dyskinesias fail to respond to 5HT1A agonist in the long-term. |
| 001772 (2011) |
Dario Benincasa [Italie] ; Clelia Pellicano [Italie] ; Alessandra Fanciulli [Italie] ; Francesco E. Pontieri [Italie] | Bupropion abates dopamine agonist‐mediated compulsive behaviors in Parkinson's disease |
| 001D33 (2010) |
Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas] | Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease |
| 002348 (2009) |
Akiyuki Uzawa [Japon] ; Masahiro Mori [Japon] ; Shigeyuki Kojima [Japon] ; Satsuki Mitsuma [Japon] ; Yukari Sekiguchi [Japon] ; Toshihide Kanesaka [Japon] ; Satoshi Kuwabara [Japon] | Dopamine agonist‐induced antecollis in Parkinson's disease |
| 002615 (2008) |
Tetsuya Takahashi [Japon] ; Tetsuhito Murata [Japon] ; Yuji Wada [Japon] | Successful treatment of blepharospasm with tandospirone, a 5‐HT1A partial agonist: A case report |
| 002C01 (2007) |
Kumar M. Prakash ; Anthony E. Lang | Reversible dopamine agonist induced anterocollis in a multiple system atrophy patient |
| 002E87 (2007) |
Andrew H. Evans [Australie] ; Helmut Butzkueven [Australie] | Dopamine agonist‐induced pathological gambling in restless legs syndrome due to multiple sclerosis |
| 003518 (2006) |
Melissa J. Nirenberg [États-Unis] ; Cheryl Waters [États-Unis] | Compulsive eating and weight gain related to dopamine agonist use |
| 003589 (2006) |
Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France] | Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors |
| 003845 (2005) |
Zhi Liu [Japon] ; Ryuji Sakakibara [Japon] ; Takeo Odaka [Japon] ; Tomoyuki Uchiyama [Japon] ; Tomoyuki Uchiyama [Japon] ; Tatsuya Yamamoto [Japon] ; Takashi Ito [Japon] ; Masato Asahina [Japon] ; Kazuya Yamaguchi [Japon] ; Taketo Yamaguchi [Japon] ; Takamichi Hattori [Japon] | Mosapride citrate, a novel 5‐HT4 agonist and partial 5‐HT3 antagonist, ameliorates constipation in parkinsonian patients |
| 003931 (2005) |
Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] | End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study |
| 003937 (2005) |
William Bara-Jimenez [États-Unis] ; Francesco Bibbiani [États-Unis] ; Michael J. Morris [États-Unis] ; Tzvetelina Dimitrova [États-Unis] ; Abdullah Sherzai [États-Unis] ; Maral M. Mouradian [États-Unis] ; Thomas N. Chase [États-Unis] | Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease |
| 003A19 (2005) |
Valerie E. Kelly [États-Unis] ; Amy J. Bastian [États-Unis] | Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements |
| 003A65 (2005) |
ZHI LIU [Japon] ; Ryuji Sakakibara [Japon] ; Takeo Odaka [Japon] ; Tomoyuki Uchiyama [Japon] ; Tomoyuki Uchiyama [Japon] ; Tatsuya Yamamoto [Japon] ; Takashi Ito [Japon] ; Masato Asahina [Japon] ; Kazuya Yamaguchi [Japon] ; Taketo Yamaguchi [Japon] ; Takamichi Hattori [Japon] | Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in Parkinsonian patients |
| 003A71 (2005) |
William Bara-Jimenez [États-Unis] ; Francesco Bibbiani [États-Unis] ; Michael J. Morris [États-Unis] ; Tzvetelina Dimitrova [États-Unis] ; Abdullah Sherzai [États-Unis] ; Maral M. Mouradian [États-Unis] ; Thomas N. Chase [États-Unis] | Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease |
| 003C21 (2004) |
Karin Stiasny-Kolster [Allemagne] ; Ralf Kohnen [Allemagne] ; Erwin Schollmayer [Allemagne] ; J. Carsten Möller [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: A double‐blind, placebo‐controlled pilot study |
| 003E51 (2004) |
Karin Stiasny-Kolster [Allemagne] ; Ralf Kohnen [Allemagne] ; Erwin Schollmayer [Allemagne] ; J. Carsten Möller [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of Restless Legs Syndrome: A double-blind, placebo-controlled pilot study |
| 004660 (2001) |
Frithjof Tergau [Allemagne] ; Stephan Wischer [Allemagne] ; Christian Wolf [Allemagne] ; Walter Paulus [Allemagne] | Treatment of restless legs syndrome with the dopamine agonist alpha‐dihydroergocryptine |
| 004664 (2001) |
J. Thomas Hutton [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Jorge L. Juncos [États-Unis] ; William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Peter A. Lewitt [États-Unis] ; Ali Samii [Canada] ; Joseph K. C. Tsui [Canada] ; Donald B. Calne [Canada] ; Cheryl H. Waters [États-Unis] ; Vincent P. Calabrese [États-Unis] ; James P. Bennett [États-Unis] ; Richard Barrett [États-Unis] ; Jerry L. Morris [États-Unis] | Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study |
| 004760 (2001) |
Fabrizio Stocchi ; Laura Vacca ; Alfredo Berardelli ; Francesca De Pandis ; Stefano Ruggieri | Long‐duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half‐life |
